2096 — Simcere Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$14.20bn
- HK$13.56bn
- CNY6.61bn
- 73
- 41
- 20
- 38
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | PRESS | PRESS |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5,037 | 4,509 | 5,000 | 6,324 | 6,608 |
Cost of Revenue | |||||
Gross Profit | 4,148 | 3,609 | 3,920 | 4,997 | 4,984 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,865 | 3,582 | 3,551 | 5,463 | 5,896 |
Operating Profit | 1,171 | 927 | 1,449 | 861 | 712 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 1,082 | 805 | 1,402 | 886 | 740 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,004 | 664 | 1,499 | 927 | 714 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,004 | 670 | 1,507 | 931 | 715 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,004 | 670 | 1,507 | 931 | 715 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.429 | 0.289 | 0.477 | 0.358 | 0.085 |
Dividends per Share |